Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Loser

Pharmacyclics Incorporated (PCYC) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.9%. By the end of trading, Pharmacyclics Incorporated fell $1.46 (-2.7%) to $53.05 on average volume. Throughout the day, 1.3 million shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 1.2 million shares. The stock ranged in price between $51.38-$54.21 after having opened the day at $52.93 as compared to the previous trading day's close of $54.51. Other company's within the Drugs industry that declined today were: K-V Pharmaceutical Company (KV.B), down 21.2%, Reliv' International (RELV), down 13.6%, Ampio Pharmaceuticals (AMPE), down 12.3%, and ACADIA Pharmaceuticals (ACAD), down 8.5%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $3.65 billion and is part of the health care sector. The company has a P/E ratio of 240.3, below the average drugs industry P/E ratio of 264.4 and above the S&P 500 P/E ratio of 17.7. Shares are up 256.7% year to date as of the close of trading on Thursday. Currently there are seven analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, premium valuation and weak operating cash flow.

• You can view the full Pharmacyclics Ratings Report.

On the positive front, Opexa Therapeutics (OPXA), up 86%, Cormedix (CRMD), up 19.1%, Affymax (AFFY), up 15.8%, and Cell Therapeutics (CTIC), up 12.4%, were all gainers within the drugs industry with Pfizer (PFE) being today's featured drugs industry winner.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

 

For more information on Pharmacyclics Incorporated click any of the following:

• Pharmacyclics Incorporated Stock Price

• Pharmacyclics Incorporated Analyst Ratings

• Pharmacyclics Incorporated Key Stats & Profile

• Pharmacyclics Incorporated Earnings

• Pharmacyclics Incorporated Ratio Comparison

• Pharmacyclics Incorporated Growth Rates

• Pharmacyclics Incorporated Balance Sheet

• Pharmacyclics Incorporated Cash Flow

• Pharmacyclics Incorporated Income Statement